Michael Hedvat

2.0k citations

16 papers · 953 indexed · h-index 10

Impact in

Oncology top 10%
- Cytokine Signaling Pathways and Interactions
- CAR-T cell therapy research
Cellular and Molecular Neuroscience top 10%
- Neuroscience and Neuropharmacology Research

Papers in ⓘ

Oncology 12
- CAR-T cell therapy research 6
- Cytokine Signaling Pathways and Interactions 4
- Cancer Immunotherapy and Biomarkers 3
Molecular Biology 8
- Angiogenesis and VEGF in Cancer 2

Co-authors: John C. Reed (4 shared papers)Paul B. Fisher (4 shared papers)Fan Yang (3 shared papers)Swadesh K. Das (3 shared papers)Devanand Sarkar (3 shared papers)Rupesh Dash (3 shared papers)Maurizio Pellecchia (3 shared papers)John L. Stebbins (2 shared papers)
Journals: Cancer Research (5 papers)Molecular Cancer Therapeutics (3 papers)Journal of Cellular Physiology (2 papers)Genes & Development (1 paper)Molecular Cancer Research (1 paper)
Partner nations: United States South Korea

In The Last Decade

Michael Hedvat

16 papers receiving 941 citations

Peers

Countries citing papers authored by Michael Hedvat

Since Specialization

Citations

This map shows the geographic impact of Michael Hedvat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Hedvat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Hedvat more than expected).

Fields of papers citing papers by Michael Hedvat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Hedvat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Hedvat. The network helps show where Michael Hedvat may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Hedvat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Hedvat Line = papers co-authored together Michael Hedvat links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics Journal of Cellular Physiology ·Keetae Kim, Seok‐Geun Lee, Timothy P. Kegelman, Zhao-zhong Su, Swadesh K. Das, Rupesh Dash, Santanu Dasgupta, Paola M. Barral, Michael Hedvat, Paul Diaz, John C. Reed, John L. Stebbins, Maurizio Pellecchia, Devanand Sarkar, Paul B. Fisher	2010	318
2	Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda -7/IL-24–mediated toxicity Proceedings of the National Academy of Sciences ·Rupesh Dash, Belal Azab, Bridget A. Quinn, Xue‐Ning Shen, Xiangyang Wang, Swadesh K. Das, Mohamed Rahmani, Jun Wei, Michael Hedvat, Paul Dent, Igor P. Dmitriev, David T. Curiel, Steven Grant, Bainan Wu, John L. Stebbins, Maurizio Pellecchia, John C. Reed, Devanand Sarkar, Paul B. Fisher	2011	101
3	Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3 Molecular Cancer Therapeutics ·Fan Yang, Christine E. Brown, Ralf Buettner, Michael Hedvat, Renate Starr, Anna Scuto, Anne Schroeder, Michael C. Jensen, Richard Jove	2010	97
4	Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways Molecular Cancer Research ·Fan Yang, Veronica Jové, Xin Hong, Michael Hedvat, Timothy Van Meter, Hua Yu	2010	94
5	Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480 Cancer Research ·Xin Hong, Andreas Herrmann, Karen L. Reckamp, Wang Zhang, Sumanta K. Pal, Michael Hedvat, Chunyan Zhang, Wei Liang, Anna Scuto, Shaobu Weng, Deborah Morosini, Zhu Cao, Michael Zinda, Robert A. Figlin, Dennis Huszar, Richard Jove, Hua Yu	2011	93
6	Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas Molecular Cancer Therapeutics ·Fan Yang, Timothy Van Meter, Ralf Buettner, Michael Hedvat, Wei Liang, Claudia Kowolik, Nilesh Mepani, Janni Mirosevich, Sangkil Nam, Mike Y. Chen, Gary Tye, Mark Kirschbaum, Richard Jove	2008	78
7	Endoplasmic reticulum protein BI-1 regulates Ca²⁺-mediated bioenergetics to promote autophagy Genes & Development ·Renata Sano, Ying-Chen Hou, Michael Hedvat, Ricardo G. Correa, Chih‐Wen Shu, Maryla Krajewska, Paul Diaz, Craig M. Tamble, Giovanni Quarato, Roberta A. Gottlieb, M. Yamaguchi, Victor Nizet, Russell Dahl, David D. Thomas, Stephen W. G. Tait, Douglas R. Green, Paul B. Fisher, Shu-ichi Matsuzawa, John C. Reed	2012	76
8	Enhanced delivery of mda‐7/IL‐24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative BI‐97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells Journal of Cellular Physiology ·Belal Azab, Rupesh Dash, Swadesh K. Das, Sujit K. Bhutia, Xue‐Ning Shen, Bridget A. Quinn, Siddik Sarkar, Xiang‐Yang Wang, Michael Hedvat, Igor P. Dmitriev, David T. Curiel, Steven Grant, Paul Dent, John C. Reed, Maurizio Pellecchia, Devanand Sarkar, Paul B. Fisher	2011	42
9	Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ Cancer Cell ·Michael Hedvat, Anjali Jain, Dennis A. Carson, Lorenzo M. Leoni, Ganghua Huang, Stuart Holden, Desheng Lu, Maripat Corr, William T. Fox, David B. Agus	2004	28
10	A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies Molecular Cancer Therapeutics ·Gregory L. Moore, Veronica G. Zeng, Juan E. Diaz, Christine Bonzon, Kendra N. Avery, Rumana Rashid, Jing Qi, Dong Hyun. Nam, Jonathan Jacinto, Matthew A. Dragovich, Yoon Kyung Kim, Karen P. Balcazar, Charles G. Bakhit, Araz Eivazi, Hanh Nguyen, Umesh S. Muchhal, David E. Szymkowski, John R. Desjarlais, Michael Hedvat	2024	11
11	Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation Cancer Research ·Michael Hedvat, Christine Bonzon, Matthew J. Bernett, Gregory L. Moore, Kendra N. Avery, Rumana Rashid, Alex Nisthal, Suzanne Schubert, Rajat Varma, Sung‐Hyung Lee, Liz Bogaert, Irene Leung, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais	2018	7
12	The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo Cancer Research ·Wei Liang, Andreas Herrmann, Michael Hedvat, Jianming Lu, Yun Yen, Wei Wen, Frank Lee, Richard Jove	2008	3
13	697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors SHILAP Revista de lepidopterología ·Michael Hedvat, Veronica G. Zeng, Juan E. Diaz, Christine Bonzon, Kendra N. Avery, Rumana Rashid, Irene Leung, Norm Bartlow, Charles G. Bakhit, Matthew A. Dragovich, Liz Bogart, Umesh S. Muchhal, John R. Desjarlais, Gregory L. Moore	2020	2
14	Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models Cancer Research ·Alex Nisthal, Matthew A. Dragovich, Erik Pong, Veronica G. Zeng, Michael Hedvat, Christine Bonzon, Kendra N. Avery, Rumana Rashid, Connie Ardila, Umesh S. Muchhal, Gregory L. Moore, Seung Y. Chu, John R. Desjarlais	2020	1
15	698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors SHILAP Revista de lepidopterología ·Veronica G. Zeng, Gregory L. Moore, Juan E. Diaz, Christine Bonzon, Kendra N. Avery, Ruschelle Love, Matthew A. Dragovich, Rumana Rashid, Irene Leung, Michael Hackett, Jing Qi, Charles G. Bakhit, Umesh S. Muchhal, Norman J. Barlow, John R. Desjarlais, Michael Hedvat	2021	1
16	Abstract 1880: PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors Cancer Research ·Gregory L. Moore, Veronica G. Zeng, Juan E. Diaz, Christine Bonzon, Kendra N. Avery, Ruschelle Love, Matthew A. Dragovich, Rumana Rashid, Michael Hackett, Irene Leung, Jing Qi, Charles G. Bakhit, Umesh S. Muchhal, Norman J. Barlow, John R. Desjarlais, Michael Hedvat	2021	1

About Michael Hedvat

Michael Hedvat is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Immunology and Pathology and Forensic Medicine, having authored 16 papers that have together received 953 indexed citations. Recurring topics across this work include CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Cytokine Signaling Pathways and Interactions (4 papers), Immunotherapy and Immune Responses (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Angiogenesis and VEGF in Cancer (2 papers), Virus-based gene therapy research (2 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Oncology (315 citations), Cellular and Molecular Neuroscience (193 citations), Developmental Neuroscience (41 citations), Biological Psychiatry (20 citations) and Neurology (62 citations). Michael Hedvat has collaborated with scholars based in United States and South Korea. Frequent co-authors include John C. Reed, Paul B. Fisher, Fan Yang, Swadesh K. Das, Devanand Sarkar, Rupesh Dash, Maurizio Pellecchia, John L. Stebbins, Paul Diaz and Richard Jove. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Journal of Cellular Physiology, Genes & Development and Molecular Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact